The outcome of community-acquired pneumonia in patients with chronic lung disease: A case-control study

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Dusemunda, Frank ^a   Chronisb, Joannis ^a   Batya, Florent ^a   Albrichc, Werner C ^a   Martin, H ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Asthma; Chronic lung disease; Community acquired pneumonia; COPD; Interstitial lung disease; Outcome

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLEURA EFFUSION; PLEURA EMPYEMA; SWITZERLAND; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED INFECTION; COMPLICATION; EMPYEMA; HEART FAILURE; LENGTH OF STAY; LUNG DISEASE; MIDDLE AGED; PLEURAL EFFUSION; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASTHMA; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; EMPYEMA; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; LENGTH OF STAY; LUNG ABSCESS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PLEURAL EFFUSION; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; SWITZERLAND; TREATMENT OUTCOME;

EID: 84929054416     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.14013     Document Type: Article

References (22)

1. http://www.cdc.gov/nchs/data/nhds/2average/2010ave2-firstlist.pdf.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl2):S27.
3. Almirall J, Bolíbar I, Balanzó X, González CA. Risk factors for community-acquired pneumonia in adults: A population-based case-control study. EurRespir J. 1999;13(2):349.
4. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with communityacquired pneumonia. Thorax. 2009;64(7):592-7.
5. Cillóniz C, Ewig S, Polverino E, Muñoz-Almagro C, Marco F, Gabarrús A, et al. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes. Clin Microbiol Infect. 2012;18(11):1134-42.
6. Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern Med. 2013;52(3):317-24.
7. Eurich DT, Lee C, Marrie TJ, Majumdar SR. Inhaled corticosteroids and risk of recurrent pneumonia: A population-based, nested case-control study. Clin Infect Dis. 2013;57(8):1138-44.
8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
9. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139(3):505-12.
10. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: A meta-analysis. Arch Intern Med. 2009;169 (3):219-29.
11. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and metaanalysis. JAMA. 2008;300(20):2407-16.
12. Sellares J, López-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E, et al. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community- Acquired Pneumonia. Am J Respir Crit Care Med. 2013;187(11):1241-8.
13. Loke YK, Kwok CS, Wong JM, Sankaran P, Myint PK. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract. 2013;67(5):477-87.
14. Marzoratti L, Iannella HA, Waterer GW. Inhaled corticosteroids and the increased risk of pneumonia. Ther Adv Respir Dis. 2013;7(4):225-34.
15. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: A retrospective claims data analysis. Int J COPD. 2013;8:295-304.
16. To M, To Y, Yamada H, Ogawa C, Otomo M, Suzuki N, et al. Influence of inhaled corticosteroids on community-acquired pneumonia in patients with bronchial asthma. Intern Med. 2004;43(8):674-8.
17. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis. 2014;21(9):229-38.
18. Segal LN, Rom WN, Weiden MD. Lung Microbiome for Clinicians. New Discoveries about Bugs in Healthy and Diseased Lungs. Ann Am Thorac Soc. 2014;11(1):108-16.
19. Martinez FJ, Erb-Downward JR, Huffnagle GB. Significance of the microbiome in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;Suppl:170-9.
20. Crisafulli E, Menéndez R, Huerta A, Martinez R, Montull B, Clini E, et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest. 2013;143 (4):1009-17.
21. Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet. 2004;364(9435):703-5.
22. Derrien M, Van Baarlen P, Hooiveld G, Norin E, Müller M, de Vos WM. Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila. Front Microbiol 2011;2:166.